Spinal cord injury
Drug research and approvals for spinal cord injury: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 379 studies of spinal cord injury are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 2 approved and 17 open orphan designations naming it.
- Recruiting worldwide: 379
- Trials authorized in Canada: 8
- FDA orphan approvals: 2
- EU medicines: 0
- Tracking Function in SCINCT07938996 · Not reported · Glasgow Caledonian University · starts Oct 30, 2026
- An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices…NCT07929792 · Not applicable · Neuralink Corp · starts Nov 1, 2026
- Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCINCT07922122 · Not applicable · TryAbility LLC · starts Jun 6, 2026
- Functional Electrical Stimulation vs Transcutaneous Stimulation in Patients With Subacute Spinal Cord InjuryNCT07911657 · Not applicable · Center for Veterans Research and Education · starts Jun 18, 2026
- tSCS Combined With Rehabilitation Training in Treating Paraplegic Patients After SCINCT07907952 · Not applicable · Beijing Tsinghua Chang Gung Hospital · starts Dec 1, 2024
- Informational Needs of Caregivers of Patients With Neuromotor Disease in Rehabilitation Hospitalization: Validation…NCT07903298 · Not applicable · Istituti Clinici Scientifici Maugeri SpA · starts Sep 15, 2025
- A Rehabilitation Data Collection Study in Patients With Spinal Cord InjuryNCT07901985 · Not reported · Seoul National University Hospital · starts Jul 7, 2024
- Comparison Between Objective Biomechanical Cost and Perceived Physical Demand in Manual Wheelchair Users During…NCT07897214 · Not applicable · Centre Médico-Chirurgical de Réadaptation des Massues Croix Rouge Française · starts Oct 19, 2026
- Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord InjuryNCT07894991 · Phase 2 · Kessler Foundation · starts Sep 21, 2026
How its trials ended
1,704 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 255 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.
- Completed, result not reported73543%
- Ongoing47728%
- Status unknown23714%
- Stopped: other or unclear946%
- Met its primary endpoint915%
- Stopped: enrollment or feasibility272%
- Stopped: funding151%
- Missed its primary endpoint131%
- Stopped: sponsor or business decision101%
- Stopped: lack of efficacy5<1%
| Sep 10, 2026 | A trial investigating the efficacy and safety of nvg 291 in subjects with chronic spinal cord injury - a randomized, double-blind, placebo-controlled…NVG-291 | Nervgen Pharma Corp. | Pending |
| Mar 11, 2025 | Low oxygen therapy as a cardiac treatment for improving 24-hour blood pressure stability in spinal cord injuryOxygen/ Nitrogen/ Carbon dioxide | University of British Columbia, School of Health and Exercise Science | Pending |
| Dec 22, 2022 | Effects of the serotonin precursor, 5-hydroxytryptophan (5-htp), on the injured human spinal cordCarbidopa | Governors of The University of Alberta | Ongoing |
| Oct 7, 2021 | Can brief exposure to hyperoxia improve function after chronic spinal cord injury?Oxygen/ Oxygen-nitrogen | Governors of The University of Alberta | Ongoing |
| Feb 24, 2021 | A phase 2a,randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MT-3921 in subjects with acute traumatic cervical spinal…MT-3921 | Mitsubishi Tanabe Pharma | Pending |
| Dec 17, 2019 | A randomized, double-blind, placebo-controlled proof of concept study to assess the safety and efficacy of elezanumab in acute traumatic cervical spinal cord…Elezanumab (ABT-555) | AbbVie | Closed |
| Sep 11, 2019 | Effects of baclofen on presynaptic inhibition in humansBaclofen | Governors of The University of Alberta | Ongoing |
| Apr 15, 2016 | A phase 2b/3, double-blind, randomized, placebo controlled, multicenter study to assess the efficacy and safety of VX-210 in subjects with acute traumatic…VX-210 / Tisseel | Vertex Pharmaceuticals | Ongoing |
| Sep 18, 2019 | OzobaxTreatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and… | Metacel Pharmaceuticals, LLC | Approved |
| Jun 25, 1992 | Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable… | Medtronic, Inc. | Approved |
| Jul 14, 2025 | FGFR and ITGB1 agonist peptide amphiphile scaffoldTreatment of acute spinal cord injury | Amphix Bio | Designated |
| Jun 10, 2025 | Oremepermin alfaTreatment of acute spinal cord injury | Kringle Pharma, Inc. | Designated |
| Oct 26, 2023 | Mesenchymal stem cell (MSC) derived small extracellular…Treatment of Acute Spinal Cord Injury | NurExone Biologic, Ltd. | Designated |
| Nov 20, 2018 | Humanized connexin 43 monoclonal antibodyTreatment of acute spinal cord injury | AlaMab Therapeutics, Inc. | Designated |
| Feb 2, 2016 | Oligodendrocyte progenitor cellsTreatment of acute spinal cord injury | Lineage Cell Therapeutics, Inc. | Designated |
| Sep 29, 2015 | GlyburideTreatment of acute spinal cord injury | Remedy Pharmaceuticals, Inc. | Designated |
| Dec 3, 2012 | Porcine GM1 gangliosideTreatment of acute spinal cord injury | TRB Chemedica International S.A. | Designated |
| Feb 1, 2008 | Autologous olfactory neural progenitorsTreatment of spinal cord injury patients with ASIA Impairment grades A, B, or C | RhinoCyte, Inc. | Designated |
| Nov 18, 2005 | Recombinant deriative of C3 transferaseTreatment of acute spinal cord injury | Vertex Pharmaceuticals, Inc. | Designated |
| Jul 7, 2005 | Contulakin-GIntrathecal treatment of neuropathic pain associated with spinal cord injury | Cognetix, Inc. | Designated |
| Apr 26, 2005 | L-threonyl-L-prolyl-L-prolyl-L-threonineTreatment of neuropathic pain associated with spinal cord injury | Nyxis Neurotherapies, Inc. | Designated |
| Sep 3, 2004 | Autologous incubated macrophageTherapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury | Proneuron Biotechnologies, Inc. | Designated |
| Mar 12, 2002 | AlbuterolPrevention of paralysis due to spinal cord injury | MotoGen, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA